BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...of CEO Simon Allen, will remain on CohBar’s board. After completing its reverse merger with Vital Therapies Inc....
BioCentury | Jan 11, 2019
Company News

Immunic plans to go public via Vital Therapies

...own about 11%. Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Immunic AG, Martinsried, Germany Business: Autoimmune Shannon Lehnbeuter IMU-838 Immunic AG Vital Therapies Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...the study this quarter (see “Seeking Validation”). The worst performing company in the tier was Vital Therapies Inc....
...OptiNose Inc. (NASDAQ:OPTN), Yardley, Penn. Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), Shanghai, China Vital Therapies Inc....
...Ltd. BGI Genomics Co. Ltd. BioArctic AB Illumina Inc. Innovate Biopharmaceuticals Inc. Ionis Pharmaceuticals Inc. OptiNose Inc. Shanghai Fosun Pharmaceutical Group Co. Ltd. Vital Therapies Inc. 3Q18...
BioCentury | Sep 13, 2018
Clinical News

Vital discontinues ELAD system after Phase III miss

...certain subgroups of patients may benefit from ELAD (see "ELAD System: Phase III Data" ). Vital Therapies Inc....
...least day 91; proportion of survivors at day 91 Status: Development discontinued Milestone: NA Brian Moy ELAD system Vital Therapies Inc....
BioCentury | Sep 12, 2018
Clinical News

Vital falls on discontinuation of ELAD system

...may benefit from ELAD (see "Vital's ELAD Misses in Liver Failure Phase III" ). Brian Moy ELAD system Vital Therapies Inc....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...two copies of the ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation MAA approval 2H18 Vital Therapies Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Prevent cytomegalovirus (CMV) reactivation in CMV-seropositive hematopoietic stem cell transplant recipients Ph III data 1Q18 Vital Therapies Inc....
BioCentury | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

...Misfeldt will serve as interim CEO while the company seeks a replacement. Liver failure company Vital Therapies Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...$80.5 $361.6 $407.5 13% Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX) 3/22/17 $13.8 $21.0 $28.3 35% Vital Therapies Inc....
BioCentury | Mar 23, 2017
Financial News

Vital Therapies completes follow-on

...On March 22, acute liver failure company Vital Therapies Inc. (NASDAQ:VTL) raised $35 million through the sale of...
...a follow-on underwritten by Raymond James and National Securities Corp. Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Alex Himes Vital Therapies Inc....
Items per page:
1 - 10 of 59
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...of CEO Simon Allen, will remain on CohBar’s board. After completing its reverse merger with Vital Therapies Inc....
BioCentury | Jan 11, 2019
Company News

Immunic plans to go public via Vital Therapies

...own about 11%. Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Immunic AG, Martinsried, Germany Business: Autoimmune Shannon Lehnbeuter IMU-838 Immunic AG Vital Therapies Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...the study this quarter (see “Seeking Validation”). The worst performing company in the tier was Vital Therapies Inc....
...OptiNose Inc. (NASDAQ:OPTN), Yardley, Penn. Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), Shanghai, China Vital Therapies Inc....
...Ltd. BGI Genomics Co. Ltd. BioArctic AB Illumina Inc. Innovate Biopharmaceuticals Inc. Ionis Pharmaceuticals Inc. OptiNose Inc. Shanghai Fosun Pharmaceutical Group Co. Ltd. Vital Therapies Inc. 3Q18...
BioCentury | Sep 13, 2018
Clinical News

Vital discontinues ELAD system after Phase III miss

...certain subgroups of patients may benefit from ELAD (see "ELAD System: Phase III Data" ). Vital Therapies Inc....
...least day 91; proportion of survivors at day 91 Status: Development discontinued Milestone: NA Brian Moy ELAD system Vital Therapies Inc....
BioCentury | Sep 12, 2018
Clinical News

Vital falls on discontinuation of ELAD system

...may benefit from ELAD (see "Vital's ELAD Misses in Liver Failure Phase III" ). Brian Moy ELAD system Vital Therapies Inc....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...two copies of the ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation MAA approval 2H18 Vital Therapies Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Prevent cytomegalovirus (CMV) reactivation in CMV-seropositive hematopoietic stem cell transplant recipients Ph III data 1Q18 Vital Therapies Inc....
BioCentury | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

...Misfeldt will serve as interim CEO while the company seeks a replacement. Liver failure company Vital Therapies Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...$80.5 $361.6 $407.5 13% Therapix Biosciences Ltd. (Tel Aviv:TRPX; NASDAQ:TRPX) 3/22/17 $13.8 $21.0 $28.3 35% Vital Therapies Inc....
BioCentury | Mar 23, 2017
Financial News

Vital Therapies completes follow-on

...On March 22, acute liver failure company Vital Therapies Inc. (NASDAQ:VTL) raised $35 million through the sale of...
...a follow-on underwritten by Raymond James and National Securities Corp. Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Alex Himes Vital Therapies Inc....
Items per page:
1 - 10 of 59